tbuckley/cabot-search huggingface dataset:
CLINICAL STUDIES OF QUINIDIN
Authors: JAMES G. CARR
Journal: JAMA (1923)

This paper embodies the results of the study of sixty-one cases of auricular fibrillation treated with quinidin sulphate in the wards of the Cook County Hospital. To the sixty-one patients under observation, seventy courses of quinidin were given. The patients ranged in age from 25 to 79. Twenty-five of the patients were under 40. In thirty-three cases the heart disease was of the rheumatic type, and in sixteen, of the arteriosclerotic; in the others, various etiologic types were represented. The duration of the heart disease ranged from a few weeks to many years; as to the duration of the fibrillation, we have no data of value. Four conditions governed us in the selection of cases. 1. Compensation was present at least to such a degree that the patient had no edema and could be up and about the ward without dyspnea. No patients were given the quinidin in the presence
Calcium deposits on IUDs may play role in infections
Authors: Elizabeth Rasche González
Journal: JAMA (1981)

Of the more than 1 million intrauterine device (IUD) users in the United States, some 8,000 to 25,000 may get severe pelvic inflammatory disease (PID), including pelvic actinomycosis. But why? Answers to the conundrum are emerging piecemeal—mainly from the ongoing examination of used IUDs. Waldemar Schmidt, MD, PhD, one of the investigators involved in this effort, has now collected some 80 IUDs both from infected women and from women who had their devices removed because they wished to bear children. At the recent meeting of the International Academy of Pathology's United States—Canadian Division, held in Chicago, Schmidt presented information on 20 of these IUDs, all removed from women with pelvic actinomycosis. The most provocative new finding, he announced, was the presence of calcium deposits on the devices. Previously, Schmidt had noted that the IUD appears to change its microenvironment and that, reciprocally, the endometrium induces changes in the IUD
Synopsis of Clinical Pulmonary Disease
Authors: William R. Barclay
Journal: JAMA (1978)

This small book written for the guidance of medical students and house officers is an excellent synopsis of diseases affecting the lung. Its soft cover and small size permit it to be conveniently slipped into a jacket or coat pocket. The material it contains has been carefully divided by disease category into 30 well-written chapters, so one can quickly locate a subject of concern. The book also has an excellent index that facilitates locating specific information. Since the book has 21 contributors, the treatment of the subject matter is somewhat uneven, despite Dr Mitchell's editorial skill. Although the reproduction of x-ray films is generally poor, the abnormalities depicted can be easily discerned, and the figures have teaching value. Some chapters have been condensed to such a degree that although the book is asynopsis, the reader is left with the uneasy feeling of being left in a state of helpless ignorance.
Effect of diets low and high in refined sugars on gut transit, bile acid metabolism, and bacterial fermentation.
Authors: W Kruis, G Forstmaier, C Scheurlen, F Stellaard
Journal: Gut (1991)

Increasing consumption of refined sugar has been implicated in many gastrointestinal disorders on epidemiological grounds. Nine volunteers agreed to participate in a study comparing the effects of a diet containing 165 g refined sugar/day with a diet of only 60 g/day on gut transit, bile acid metabolism, and fermentative activity of the intestinal flora. The wet and dry weight, pH, and water content of the stools were similar on the two diets. On the high sugar diet mouth-to-anus transit time was significantly prolonged, despite a shortened mouth-to-caecum transit time. The faecal concentration of total bile acids and the faecal concentration of secondary bile acids increased significantly. Diet affected neither the serum bile acid pattern nor the concentration. Breath hydrogen tests showed significantly enhanced H2 production on the high sugar diet. We conclude that the quantity of refined sugar in the diet can significantly influence gut function and the composition of bowel contents.
Phase I/II Study of Cyclophosphamide, Doxorubicin, Fluorouracil, and Leucovorin for Treatment of Metastatic Adenocarcinoma
Authors: Howard L. Parnes, Jeffrey S. Abrams, Nancy Tait, Jon Minford, Steven L. Allen, David Duggan, Joseph Aisner
Journal: JNCI Journal of the National Cancer Institute (1991)

Leucovorin enhances the cytotoxicity of fluorouracil (5–FU) in patients with colorectal cancer and may increase the efficacy of combination chemotherapy regimens containing 5–FU. To determine the maximum tolerated dose of 5–FU with leucovorin for use in combination with cyclophosphamide and doxorubicin, we conducted a phase I/II trial in 20 patients. The doses of leucovorin (200 mg/m2 on days 1–5), cyclophosphamide (500 mg/m2 on day 1), and doxorubicin (40 mg/m2 on day 1) were held constant, while the dose of 5–FU was escalated in cohorts of patients beginning at 150 mg/m 2 on days 1–5. Cycles were repeated every 3 weeks. Significant mucositis, diarrhea, and myelosuppression were infrequently observed in patients receiving up to 250 mg/m 2 5–FU on days 1–5. In contrast, at a dose of 300 mg/m 2 on days 1–5, three of six patients had granulocyte count nadirs of less than 500/μL during the first cycle of therapy, and two of these three had platelet counts of less than 25 000/μL. In addition, two patients treated at this dose had significant mucosal toxic effects, and three had insufficient recovery to permit a second course by day 22. Among 14 patients with assessable breast cancer, there were one complete and nine partial responses (response rate 71%). Leucovorin modulation of 5–FU can be safely incorporated into combination chemotherapy with cyclophosphamide and doxorubicin and provides a highly active regimen for treatment of metastatic breast cancer. Further study will be required to determine whether the addition of leucovorin significantly enhances the activity of this regimen. [J Natl Cancer Inst 83: 1017–1020, 1991]
Acquired cutis laxa and multiple myeloma
Authors: H.C. TING, M.H. FOO, D.F. WANG
Journal: British Journal of Dermatology (1984)

Journal Article Acquired cutis laxa and multiple myeloma Get access H.C. TING, H.C. TING Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia 3597 Jalan Ismail, Kota Bahru, Kelantan, Malaysia Search for other works by this author on: Oxford Academic Google Scholar M.H. FOO, M.H. FOO Department of Foo Clinic, 3597 Jalan Ismail, Kota Bahru, Kelantan, Malaysia Search for other works by this author on: Oxford Academic Google Scholar D.F. WANG D.F. WANG Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia 3597 Jalan Ismail, Kota Bahru, Kelantan, Malaysia Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 110, Issue 3, 1 March 1984, Pages 363–367, https://doi.org/10.1111/j.1365-2133.1984.tb04645.x Published: 01 March 1984 Article history Accepted: 25 July 1983 Published: 01 March 1984
Hormone Therapy and Cardiovascular Risk
Authors: Lynn E. T. Shaffer, Carl A. Krantz
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Near Fatal Complication of Sutureless Electrode Placement
Authors: John P. Sutton
Journal: JAMA (1977)

THE AVAILABILITY of sutureless epicardial electrodes, which can be inserted with low morbidity and a relatively uncomplicated surgical approach, now provides an acceptable alternative to transvenous electrodes. We report a case in which a near fatal laceration was produced in the left ventricle in the course of insertion of a corkscrew epicardial electrode. <h3>Report of a Case</h3> A 71-year-old woman had a transvenous demand pacemaker inserted. A month later, lead failure developed secondary to electrode migration and development of an exit block. At lead repositioning, excellent stimulation and sensing thresholds were reported with a pacing system analyzer. The radiographic position was excellent, but pacing system failure again developed 12 months later. Because of two previous lead failures, an anterior transthoracic approach was selected by way of the fifth anterior rib resection and a 15-cm incision. Before making the submammary incision, the anterior pectoral pocket was opened. The pacemaker pulse interval,
Losartan and Its Metabolite E3174 Modify Cardiac Delayed Rectifier K <sup>+</sup> Currents
Authors: Ricardo Caballero, Eva Delpón, Carmen Valenzuela, Mónica Longobardo, Juan Tamargo
Journal: Circulation (2000)

Background —The effects of type 1 angiotensin II receptor antagonist losartan and its metabolite E3174 on transmembrane action potentials, hKv1.5, HERG, and I Ks currents were analyzed. Methods and Results —Guinea pig ventricular action potentials were recorded with microelectrode techniques and hKv1.5 and HERG currents with the whole-cell patch-clamp technique. I Ks was recorded in guinea pig ventricular myocytes with the perforated-nystatin-patch configuration. Losartan and E3174 transiently increased the hKv1.5 current by 8.0±1.4% and 7.4±1.6%, respectively. Thereafter, they produced a voltage-dependent block, E3174 being more potent than losartan ( P &lt;0.05) for this effect. Losartan decreased HERG currents elicited at 0 mV (23.3±4.8%), whereas E3174 increased the current (30.5±6.2%). Both drugs shifted the midpoint of the activation curve of HERG channels to more negative potentials. In ventricular myocytes, losartan and E3174 inhibited the I Ks (18.4±3.2% and 6.5±0.7%, respectively). Losartan-induced block was voltage-independent, whereas E3174 shifted the midpoint of the activation curve to more negative potentials. Losartan lengthened the duration of the action potentials at both 50% and 90% of repolarization, whereas E3174 slowed only the final phase of the repolarization process. Conclusions —These results demonstrated that at therapeutic concentrations, both losartan and E3174 modified the cardiac delayed rectifier hKv1.5, HERG, and Ks currents.
T Cell Receptor Signaling Is Limited by Docking Geometry to Peptide-Major Histocompatibility Complex
Authors: Jarrett J. Adams, Samanthi Narayanan, Baoyu Liu, Michael E. Birnbaum, Andrew C. Kruse, Natalie A. Bowerman, Wei Chen, Aron M. Levin, Janet M. Connolly, Cheng Zhu, David M. Kranz, K. Christopher Garcia
Journal: Immunity (2011)
&lt;emph type="ital"&gt;Choucoune&lt;/emph&gt;&lt;emph type="ital"&gt;(Yellow Bird)&lt;/emph&gt;
Authors: Thomas B. Cole
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors
Authors: Won Sohn, Yong-Han Paik, Ju-Yeon Cho, Ho Yeong Lim, Jem Ma Ahn, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
Journal: Journal of Hepatology (2014)
Treatment of Early Syphilis
Authors: J. W. Eames
Journal: BMJ (1949)

<h3>Objective</h3> The roll-out of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine has brought many logistical challenges, such as the absence of comprehensive stability data leading to strict handling instructions during dilution and administration. Accidental mishandling therefore presents challenging clinical dilemmas, which often led vaccine providers to err on the side of caution and discard mishandled vials rather than risk administering ineffective vaccine. This study aims to answer key questions about the vaccine’s stability to allow for a more informed decision-making process should a non-conformity occur. <h3>Methods</h3> Residual vaccine in freshly used, but appropriately stored vials collected from vaccination centres in Brighton, UK, were tested after exposure to various handling conditions and analysed by dynamic light scattering to determine the size of the lipid-mRNA nanoparticles, and gel electrophoresis to visualise the mRNA integrity and separation from the lipid formulation. <h3>Results</h3> Knocking or dropping vaccine samples from small heights resulted in lowest levels of instability, indicating low risk of compromising clinical efficacy. However, repeated drawing and injecting through 23 G needles at high speed and, more significantly, shaking and vortexing led to progressive increase in the size and polydispersity index of the lipid-mRNA nanoparticles, coupled with or caused by up to ~50% release of mRNA from the lipid formulation. This is thought to impact the vaccine’s efficacy due to lack of free mRNA protection and cellular internalisation. <h3>Conclusions</h3> These results reiterate the importance of adhering to the manufacturer’s instructions on handling, especially with regard to shaking and exposing the vaccine to excessive vibration.
REJECTIONS OF REGISTRANTS AT CAMP FOR PHYSICAL CAUSES
Authors: J. Milton Mabbott
Journal: JAMA (1918)

<h3>To the Editor:</h3> —The rejections from camp have certainly become an exceedingly important matter. Within the past few weeks I have read carefully the articles inThe Journalentitled "Physical Examinations Under the Selective Service: A Meeting of the Section on Miscellaneous Topics, Held in the Studebaker Theater. Chicago, Thursday, June 13." published, in part, July 6, and concluded, July 13, 1918. Similar meetings were held in New York. There were evidences of lack of respect on the part of one examiner for the opinions of another. Notably on page 28, first column, Dr. James B. Herrick of the District Board of Chicago is quoted as having said: Now the Army physician's examination is final and authoritative as it should be. But the reason the taunt of the returned man cuts when he hints or plainly says to the board physician that he, the board physician, evidently did not understand
Congenital Pericardial Defect Associated with Tetralogy of Fallot
Authors: FLORENCIO A. HIPONA, ANDREW B. CRUMMY
Journal: Circulation (1964)

Congenital pericardial defect is a rare anomaly with a total of 115 cases in the literature. The two cases discussed are the first reported to be associated with tetralogy of Fallot. The only known case of herniation of normal lung through a pericardial defect into the pericardial cavity is described.
Inertia on folic acid has caused thousands of unnecessary deaths
Authors: A. Ellis
Journal: BMJ (2003)

As many as 350 000 deaths could have been prevented over the last decade if the UK government had acted on the compelling evidence for the benefits of folic acid, a conference was told last week. Had flour been fortified with folic acid when the evidence regarding neural tube defects was published, thousands of people would not have died from coronary heart disease.

Godfrey Oakley, visiting professor at the department of epidemiology at the Rollin School of Public Health of Emory University, Atlanta, said: “The failure to require mandatory fortification of flour with folic acid is public health malpractice.” He was speaking at a conference in London organised by Dr Jean-Pierre Lin, consultant paediatric neurologist responsible for the spina bifida services at Guy's and St Thomas's hospitals on behalf of the charity the Little Foundation and MacKeith meetings (a product of publishers MacKeith Press).

Recent …
Thrombin-induced protein phosphorylation in human platelets.
Authors: R M Lyons, N Stanford, P W Majerus
Journal: Journal of Clinical Investigation (1975)

Intact human platelets loaded with 32PO4 contain multiple phosphorylated proteins. Thrombin treatment of intact 32PO4-loaded platelets results in a 2-6-fold increase in phosphorylation of a platelet protein (designated "peak 7" protein) of approximately 40,000 mol wt as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis and by gel filtration on Sephadex G-150. A similar increase in phosphorylation was observed in a platelet protein (designated "peak 9" protein) of approximately 20,000 mol wt. The time for half-maximal phosphorylation of peak 7 and peak 9 protein was 10-14 s. The concentration of thrombin at half-maximal phosphorylation was 0.25 U/ml for both proteins. Prior incubation of platelets with dibutyryl cyclic adenosine 3',5'-monophosphate or prostaglandin E1 inhibited thrombin-induced peak 7 and peak 9 protein phosphorylation. The erythroagglutinating phytohemagglutinin of Phaseolus vulgaris, a non-proteolytic release-inducing agent, induced peak 7 and peak 9 protein phosphorylation. Thus, the characteristics of peak 7 and peak 9 protein phosphorylation are similar to those of the platelet release reaction, suggesting that the phosphorylation of these proteins may play a role in the platelet release reaction. When platelet sonicates or the supernatant fraction from platelet sonicates were incubated with [gamma-32P]ATP there was phosphorylation of both peak 7 and peak 9 proteins. This phosphorylation was unaffected by either added thrombin or adenosine 3',5'-cyclic monophosphate (cAMP) despite the presence of the phosphodiesterase inhibitor 1-methyl-3-isobutylxanthine. Thus, the thrombin-dependent phosphorylation depends upon intact platelets. When the supernatant fraction from platelet sonicates was fractionated by histone-Sepharose affinity chromatography, two distinct protein kinase enzymes were resolved, one a cAMP-dependent holoenzyme and the other a cAMP-independent enzyme. The isolated cAMP-dependent enzyme fraction catalyzed the cAMP-(but not thrombin-) stimulated phosphorylation of a protein that co-electrophoresed with peak 7 protein.
Severe Watery Diarrhoea and Potassium Depletion Associated with an Islet-cell Tumour of Pancreas
Authors: R. A Parkins
Journal: BMJ (1961)

STUDENTS WITH ACNE VULGARISwhether or not a complaint was made, if the groups were subdivided in terms of the severity of their skin trouble.Most had not the severe, or intractable, type of lesion which is common in skin clinics.However, it is a priori probable that if neurotic difficulties contribute directly to the development of acne they would do so in the milder as well as in the more severe types of the condition.A further study is planned to examine these points and to determine whether or not those subjects who observe exacerbations of their lesions in response to stresses differ from those in whom fluctuations in severity appear to be random. SummaryA study is reported of a comparison between the personalities of students with acne who complained of it, students with acne who did not complain of it, and students free from acne.Personality was assessed by means of the Maudsley personality inventory.There was no significant difference between the mean score of the groups on neuroticism or extraversion.To complement the psychological test, the number of the students who reported psychological symptoms during the year was ascertained.They were as frequent in the control as in the acne groups.When a comparison was made between students who reported psychological symptoms and those who did not (regardless of whether or not they had acne), it was found that the group who reported psychological symptoms were significantly higher on neuroticism than the others.
CLINICAL EVALUATION OF DEXTRAN AS A PLASMA VOLUME EXPANDER
Authors: Harry W. Bowman
Journal: JAMA (1953)

At the termination of World War II, the advent of atomic destruction alerted the medical profession to the great need for emergency stockpiling of plasma and plasma substitutes. At present, three plasma substitutes are widely used, dextran, polyvinylpyrrolidone, and oxypolygelatin.  volume expander is the accepted name for these materials, since there is no true substitute for plasma or whole blood. Plasma expanders may be divided into four groups: (1) Blood derivatives: albumin, plasma, and modified globin; (2) modified proteins: gelatin and oxypolygelatin; (3) polymerized cabohydrates: dextran; (4) plastics: polyvinylpyrrolidone. 1a   My clinical experience with plasma volume expanders has been limited almost entirely to the evaluation of dextran. I have had very little experience with polyvinylpyrrolidone, and I have not used oxypolygelatin in any of my studies.  METHOD AND MATERIALS  I have administered more than 500 infusions of dextran (Plavolex), in 6% isotonic sodium chloride solution during an 18 month